CD19 CAR-T for severe autoimmune diseases
Part of Immune system & allergy clinical trials.
This trial tests whether a special immune cell treatment (CD19 CAR-T) can help people with certain severe autoimmune diseases that have not improved with standard therapies. It is a very early study to see if the treatment is safe and effective for conditions like lupus, systemic sclerosis, vasculitis, myositis, or Sjögren's syndrome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these autoimmune diseases that is active despite standard treatments: lupus (SLE), systemic sclerosis (SSc), vasculitis (AAV), inflammatory myopathy (IIM), or Sjögren's syndrome (SS).
- You are 18 to 65 years old.
- You have tried at least 3 months of steroids plus two other immune-suppressing drugs, and your disease is still active or has come back.
- Your major organs (heart, lungs, kidneys, liver, blood counts) must be working well enough, as measured by blood tests and scans.
- You cannot have other active cancers, serious infections, or recent live vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell therapy (CAR T cells) for people with severe lupus, Sjogren's syndrome, systemic sclerosis, and other autoimmune conditions that haven't improved with standard treatments. The therapy is designed to target and reset the immune system.
This trial tests a type of immune cell therapy called CAR T-cells that target CD19, for people with severe autoimmune diseases that haven't improved with standard treatments. The goal is to see if it can help calm the immune system and reduce disease activity.
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
This trial tests a new CAR-T cell therapy that targets two immune proteins (CD19 and BAFF) to treat autoimmune diseases like lupus or scleroderma. It is for people who have not improved with standard treatments.
Hear when a new Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.